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Measles outbreaks in the United States: Public health preparedness, 
control and response in healthcare settings and the community
A measles outbreak linked to an importation from Switzerland currently is ongoing in Arizona. The first case, with 
rash onset on February 12, 2008, occurred in an adult visitor from Switzerland who was hospitalized with measles 
and pneumonia. This hospital admission prompted verification of the measles immune status of approximately 
1800 healthcare personnel and vaccination of those without evidence of immunity. Through March 31, 2008, nine 
confirmed cases have been reported to the Arizona Department of Health Services, and there are two suspected 
cases (one in a Colorado resident) and hundreds of contacts under investigation. The nine case-patients range in 
age from 10 months to 50 years. All but one were infected in healthcare settings, one of the five adult case- 
patients is a healthcare worker, and all cases were unvaccinated at the time of exposure.
In January and February 2008, San Diego experienced an outbreak of 11 measles cases, with an additional case- 
patient who was exposed in San Diego but became ill in Hawaii. The index case was an unvaccinated child who 
had recently traveled to Switzerland, where a measles outbreak is ongoing (see
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5708a3.htm). Transmission in this outbreak occurred in a 
doctor's office as well as in community settings. Measles genotype D5 was identified from more than one case in 
the San Diego and Arizona outbreaks; this genotype is currently circulating in Switzerland (see 
http://www.eurosurveillance.org/edition/v13n08/080221_1.asp). Confirmed measles cases also have been 
reported from New York City (involving genotype D4, which is identical to the genotype responsible for a large 
ongoing measles outbreak in Israel; see http://www.eurosurveillance.org/edition/v13n08/080221_3.asp) and from 
Virginia (importation from India). In addition, two measles cases recently confirmed in unvaccinated siblings from 
Michigan may have resulted from exposure during a long stop-over in the Atlanta airport.
Although measles is no longer an endemic disease in the United States, it remains endemic in most countries of 
the world, including some countries in Europe. Large outbreaks currently are occurring in Switzerland and Israel.
In the United States from January 1 through March 28, 2008, 24 confirmed cases of measles resulting from 
importations from endemic countries have been reported to the Centers for Disease Control and Prevention 
(CDC). These cases highlight the ongoing risk of measles importations, the risk of spread in susceptible 
populations, and the need for a prompt and appropriate public health response to measles cases. Because of the 
severity of the disease, people with measles commonly present in physician's offices or emergency rooms and 
pose a risk of transmission to other patients and healthcare personnel in these and in inpatient hospital settings. 
Healthcare providers should remain aware that measles cases may occur in their facility and that transmission 
risks can be minimized by ensuring that all healthcare personnel have evidence of measles immunity and that 
appropriate infection control practices are followed.
Transmission and case definition
Measles is a highly contagious disease that is transmitted by respiratory droplets and airborne spread. The 
disease can result in severe complications, including pneumonia and encephalitis. The incubation period for 
measles ranges from 7 to 18 days. The diagnosis of measles should be considered in any person with a 
generalized maculopapular rash lasting > 3 days, a temperature > 101°F (38.3°C), and cough, coryza, or 
conjunctivitis. Immunocompromised patients may not exhibit rash or may exhibit an atypical rash.
Recommendations
Rapid and aggressive public health action is needed in response to measles cases. Case investigation and 
vaccination of household or other close contacts without evidence of immunity should not be delayed pending the 
return of laboratory results. Preparation for other control activities may need to be initiated before laboratory 
results are known. Control activities include isolation of known and suspected case-patients and administration of 
vaccine (at any interval following exposure) or immune globulin (within 6 days of exposure, particularly contacts < 
6 months of age, pregnant women, and immunocompromised people, for whom the risk of complications is 
highest) to susceptible contacts. For contacts who remain unvaccinated, control activities include exclusion from 
day care, school, or work and voluntary home quarantine from 7 to 21 days following exposure. Persons who are 
known contacts of measles patients and who develop fever and/or rash should be considered suspected measles 
case-patients and be appropriately evaluated by a healthcare provider. If healthcare providers are aware of the 
need to assess a suspected measles case, they should schedule the patient at the end of the day after other 
patients have left the office and inform clinics or emergency rooms if they are referring a suspected measles 
patient for evaluation so that airborne infection control precautions can be implemented prior to their arrival.
Healthcare providers should maintain vigilance for measles importations and have a high index of suspicion for 
measles in persons with a clinically compatible illness who have traveled abroad or who have been in contact with 
travelers. They should assess measles immunity in U.S. residents who travel abroad and vaccinate if necessary. 
Measles outbreaks are ongoing in Switzerland and Israel, and measles outbreaks are common throughout 
Europe. Measles is endemic in many countries, including popular travel destinations, such as Japan and India. 
Suspected measles cases should be reported immediately to the local health department, and serologic and 
virologic specimens (serum and throat or nasopharyngeal swabs) should be obtained for measles virus detection 
and genotyping. Laboratory testing should be conducted in the most expeditious manner possible.
Preventing transmission in healthcare settings
To prevent transmission of measles in healthcare settings, airborne infection control precautions (available at 
http://www.cdc.gov/ncidod/dhqp/gl_isolation.html) should be followed stringently. Suspected measles patients 
(i.e., persons with febrile rash illness) should be removed from emergency department and clinic waiting areas as 
soon as they are identified, placed in a private room with the door closed, and asked to wear a surgical mask, if 
tolerated. In hospital settings, patients with suspected measles should be placed immediately in an airborne 
infection (negative-pressure) isolation room if one is available and, if possible, should not be sent to other parts of 
the hospital for examination or testing purposes.
All healthcare personnel should have documented evidence of measles immunity on file at their work location. 
Having high levels of measles immunity among healthcare personnel and such documentation on file minimizes
the work needed in response to measles exposures, which cannot be anticipated. Recent measles exposures in 
hospital settings in three states necessitated verifying records of measles immunity for hundreds or thousands of 
hospital staff, drawing blood samples for serologic evidence of immunity when documentation was not on file at 
the work site, and vaccinating personnel without evidence of immunity.
Recommendations for vaccination
Measles is preventable by vaccination. MMR vaccine is routinely recommended for all children at 12 -15  months 
of age, with a second dose recommended at age 4 -6  years. Two doses of MMR vaccine are recommended for 
all school students and for the following groups of persons without evidence of measles immunity: students in 
post-h igh school educational facilities, healthcare personnel, and international travelers who are > 12 months of 
age. Other adults without evidence of measles immunity should routinely receive one dose of MMR vaccine. To 
prevent acquiring measles during travel, U.S. residents aged > 6 months traveling abroad should be vaccinated 
or have documentation of measles immunity before travel. Infants 6 -1 1  months of age should receive one dose 
of monovalent measles vaccine (or MMR vaccine if monovalent vaccine is not available) prior to travel.
During a measles outbreak, additional vaccine recommendations should be considered: 1) children > 12 months 
of age should receive their first dose of MMR vaccine as soon after their first birthday as possible and their 
second dose 4 weeks later, 2) healthcare facilities should strongly consider recommending one dose of MMR 
vaccine to unvaccinated healthcare personnel born before 1957 who do not have serologic evidence of immunity 
or physician documentation of measles disease, and 3) one dose of measles or MMR vaccine should be 
considered for infants > 6 months of age.
Further information on measles and measles vaccine is available at state health departments' websites and at 
http://www.cdc.gov/vaccines/vpd-vac/measles/default.htm.
Additional Sources of Information
The Centers for Disease Control and Prevention maintains a website with many informative articles and 
references on measles and the MMR vaccine. Several links are listed below.
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Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 
2007.
Measles: General Information, provides background and incidence information and links to other information, 
including laboratory tools.
MMR Vaccine Information Statement .
MMR Vaccine Questions and Answers for Clinicians.
Vaccines and Preventable Diseases: Measles Disease In-Short, provides general information about measles, 
including a description of the disease, information about symptoms, complications, transmission, and the 
vaccine and who needs it.
Vaccines and Preventable Diseases: Measles Vaccination, provides general information about the disease, 
vaccination information, beliefs and concerns, vaccine safety, and who should not be vaccinated. It also 
contains more specific information for clinicians, including technical information, recommendations, 
references and resources, provider education, and materials for patients.
Travelers' Health, including information for specific groups and settings.
Travelers' Health: Yellow Book, CDC health information for international travel 2008.
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